🇺🇸 FDA
Pipeline program

HEC585 dose A

HEC585-PF-202

Phase 2 small_molecule active

Quick answer

HEC585 dose A for Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) is a Phase 2 program (small_molecule) at Sunshine Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Sunshine Biopharma
Indication
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials